Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: Comparative effects of amlodipine and valsartan

References

• Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22–27.
   PubMed Web of Science ®Google Scholar
• Moncada S, Palmer R, Higgs E. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991; 43:109–142.
   PubMed Web of Science ®Google Scholar
• Xiao L, Liu Y, Wang N. New paradigms in inflammatory signaling in vascular endothelial cells. Am J Physiol 2014;306:H317–H325
   Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342:836–843.
   PubMed Web of Science ®Google Scholar
• Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108:2993–2999.
   PubMed Web of Science ®Google Scholar
• DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens. 1997;10:1335–1341.
   PubMed Web of Science ®Google Scholar
• Szmitko P E, Wang C-H, Weisel R D, de Almeida J R, Anderson T J, Verma S, et al. New markers of inflammation and endothelial cell activation. Part I. Circulation. 2003; 108:1917–1923.
   PubMed Web of Science ®Google Scholar
• Volpe M, Camm J, Coca A, Unger T. The cardiovascular continuum refined: A hypothesis. Blood Press. 2010;19: 273–277.
   PubMed Web of Science ®Google Scholar
• Widlanksy ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149–1160.
   PubMed Web of Science ®Google Scholar
• Deanfield JE, Halcox JP, Rabelink TJ Endothelial function and dysfunction: Testing and clinical relevance. Circulation. 2007;115:1285–1295.
   PubMed Web of Science ®Google Scholar
• Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109 Suppl 1:III27–III32.
   Web of Science ®Google Scholar
• Bechard, D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, Bertheau P, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000;37:417–425.
   PubMed Web of Science ®Google Scholar
• Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271:20458–20464.
   PubMed Web of Science ®Google Scholar
• Béchard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1). J Immunol. 2001;167:3099–3106.
   PubMed Web of Science ®Google Scholar
• Balta I, Balta S, Koryurek OM, Demirkol S, Mikhailidis DP, Celik T, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014;70:291–296.
   PubMed Web of Science ®Google Scholar
• Balta I, Balta S, Demirkol S, Mikhailidis DP, Celik T, Akhan M, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: Correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013; 25;169: 1066–1070.
   Google Scholar
• Lee W, Ku SK, Kim SW, Bae JSEndocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;22:620–630.
   Google Scholar
• Stéphane S, Claude-Alain M, Dominique D, Philippe L, Maryse D. Endocan as a biomarker of endothelial dysfunction in cancer. J Cancer Sci Ther. 2010;2:47–52.
   Google Scholar
• Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765:25–37.
   PubMed Web of Science ®Google Scholar
• Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Kurtoglu E, Demir M, et al. Endocan – A novel inflammatory indicator in newly diagnosed patients with hypertension: A pilot study. Angiology. 2014; 2014;65:773–777.
   PubMed Web of Science ®Google Scholar
• Tadzic R, Mihalj M, Vcev A, Ennen J, Tadzic A, Drenjancevic I. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney Blood Press Res. 2013;37:103–115.
   PubMed Web of Science ®Google Scholar
• Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003;42:905–910.
   PubMed Web of Science ®Google Scholar
• Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: Evidence of an anti-inflammatory action. J Clin Endocrinol Metab. 2003;88:4496–4501.
   PubMed Web of Science ®Google Scholar
• Mason RP, Jacob RF, Corbalan JJ, Kaliszan R, Malinski T. Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes. Am J Hypertens. 2014;27:482–488.
   PubMed Web of Science ®Google Scholar
• Berkels R, Egink G, Marsen TA, Bartels H, Roesen R, Klaus W. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension. 2001;37:240–245.
   PubMed Web of Science ®Google Scholar
• Taddei S, Virdis A, Ghiadoni L, Magagna A, Favilla S, Pompella A, et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension. 2001;37:943–948.
   PubMed Web of Science ®Google Scholar
• Koh KK, Han SH, Ahn JY, Chung WJ, Lee Y, Shin EK. Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int J Cardiol. 2009;133:23–31.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Press. 2013; 22:193–278.
   PubMed Web of Science ®Google Scholar
• Martin SS, Metkus TS, Horne A, Blaha MJ, Hasan R, Campbell CY, et al. Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations. Am J Cardiol. 2012;110:307–313.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa K. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens. 2008;30: 267–276.
   PubMed Web of Science ®Google Scholar
• Tzemos N, Lim PO, MacDonald TM. Valsartan improves endothelial dysfunction in hypertension: A randomized, double-blind study. Cardiovasc Ther. 2009;27:151–158.
   PubMed Web of Science ®Google Scholar